ライフサイエンスコーパス: ADL

1 ADL difficulties increased by 0.22 standard deviations (

2 ADL experienced three major development stages: slower e

3 ADL impairment was associated with an increased risk of

4 ADL should be sequentially evaluated early during treatm

5 ADL worsened by 0.93 (SE 0.05) points per year in the en

6 ADLs and IADLs scales were applied.

7 covered to premorbid level (difference, 0.09 ADL; 95% CI, -0.27-0.44), but stroke patients admitted t

8 ance, or needing assistance to perform >or=1 ADL task.

9 s) disability, defined as dependence in >/=3 ADLs for 2 consecutive annual interviews or for 1 interv

10 ; number of dependent ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 points); congestive heart

11 ally frail, or severely disabled (ie, in 3-4 ADLs) at onset were less likely to recover than those wh

12 ecovered (ie, regained independence in all 4 ADLs) within 12 months of their initial disability episo

13 1-3.81; IADL impairment: OR 3.12, 2.20-4.41; ADL impairment: OR 1.58, 1.11-2.24).

14 ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 points); congestive heart failure (2 points); ca

15 1.5-7.2) and recover ADLs (difference, 0.63 ADL; 95% CI, 0.20-1.07).

16 as performed (P < .01), a difference of 0.67 ADL abilities retained by the GC group compared with the

17 5% CI 1.3-2.8; p = 0.001, p for trend across ADL categories = 0.001) after controlling for a broad ra

18 ing by disrupting this balance: it activates ADL and increases expression of ins-16, and this cellula

19 In both groups, ADCS ADL scores declined over 24 months.

20 At the primary end point of 24 months, ADCS ADL scores did not differ between groups (mean differenc

21 Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Phys

22 Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Phys

23 % CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-tr

24 .43, -2.06 to 1.20, p=0.9323; change in ADCS-ADL score compared with control [-8.22, 95% CI -9.63 to

25 y-Activities of Daily Living Inventory (ADCS-ADL) scales from baseline assessed at week 65 in the mod

26 y-Activities of Daily Living Inventory; ADCS-ADL), and model the relationship between cognitive measu

27 bo group in activities of daily living (ADCS-ADL difference in slope 3.98 [95% CI 0.33 to 7.62] point

28 ative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78).

29 ative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and highe

30 ive Studies-activities of daily living (ADCS-ADL) scale.

31 e per day had no significant effects on ADCS-ADL and ADAS-cog and had a negative effect on CDR-sb (-5

32 Study activities of daily living scale (ADCS-ADL), and the clinical dementia rating sum of boxes (CDR

33 Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse

34 to tarenflurbil in the ADAS-cog and the ADCS-ADL (p>or=0.10); therefore, these groups were analysed s

35 w significantly greater declines on the ADCS-ADL or Wechsler Memory Scale.

36 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1

37 The ADCS-ADL scores also worsened in all groups (mean change at w

38 disease were assessed on the UPSA, the ADCS-ADL, and a battery of neurocognitive tests.

39 impairments on the UPSA but not on the ADCS-ADL.

40 an (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.9

41 Additionally, ADL and IADL difficulties among men and women contribute

42 ations in activities of daily living (ADLs) (ADLs and instrumental ADLs), emergency department visits

43 On the advanced ADL, 58% of patients reported difficulty with errands, 6

44 n index, the odds ratio for the effect of an ADL score of less than 12 of 15 on mortality is 1.83 (95

45 MRS scores (p<0.001), mobility (p<0.001) and ADL (p=0.002) following inpatient treatment.

46 ]), verbal fluency (-0.34 words [0.07]), and ADL (0.64 points [0.04]) during the first 25 years of di

47 The strong relationship of arthritis and ADL disability was partially explained by demographic, h

48 he sensation of noxious chemicals by ASH and ADL neurons; it requires the genes ocr-2 and osm-9, whic

49 J and ASK gustatory neurons, and the ASH and ADL nociceptors, respond to a rise in CO2 with a rise in

50 Ablation of the nociceptive neurons ASH and ADL transforms social animals into solitary feeders.

51 4, acting in the nociceptive neurons ASH and ADL.

52 expression in ASJ, which antagonizes ASI and ADL.

53 G is gap-junctionally coupled to the ASK and ADL pheromone sensors that respectively drive pheromone

54 come in the mother's residence ZIP code, and ADL during the first 90 days after the EDC were factors

55 f transition to combined lower extremity and ADL difficulty first over 72 months.

56 a dose-related response in ICARS, FARS, and ADL scores.

57 ith improvement in neurological function and ADL in patients with FA.

58 tremic patients matched for age, gender, and ADL served as reference group.

59 investigate the item sequence of 11 IADL and ADL combined into a single scale and functional trajecto

60 We evaluated IADL and ADL data collected at home every 2-3 years over a 24-yea

61 then an overlapping of concomitant IADL and ADL, with bathing and dressing being the earliest ADL lo

62 evant Nagi Disability Scale, IADL Scale, and ADL Scale tasks.

63 %-42.2%; P = .03) between the 2 surveys, and ADL impairment did not change.

64 difficulty in both lower extremity tasks and ADL over 72 months in a cohort of initially high functio

65 e treadmill exercises (at 2 and 3 km/h), and ADLs: ADL1 (getting dressed), ADL2 (folding 8 towels), A

66 Measures of QOL and ADLs (bathing, feeding, and so on) were not independentl

67 t of a gap junction circuit that antagonizes ADL chemical synapses.

68 The prevalence of any ADL limitation was lowest in low-risk people and increas

69 eported having limitations in performing any ADL and 11% in any instrumental ADL only.

70 Ablating the ASH, ADL, or ASK sensory neurons connected to RMG by gap junc

71 ficant deterioration in EDSS but not Barthel ADL Index scores at 1 year, but the difference between t

72 the multivariate model adjusted for baseline ADL and MAX2 index, high baseline GDS (odds ratio [OR],

73 ore likely than sudden death decedents to be ADL dependent (OR, 8.32 [95% CI, 6.46-10.73); cancer dec

74 ine, 697 remained ADL independent, 84 became ADL dependent, 41 died, and 115 were lost to followup 2

75 ion: male sex (1 point); number of dependent ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 poi

76 ent and significant predictor for developing ADL disability (adjusted odds ratio 1.5, 95% confidence

77 During ADLs, patients self-regulated activities in parallel wit

78 with bathing and dressing being the earliest ADL losses, and finally total losses for toileting, cont

79 climate and socio-economic data to evaluate ADL and its driving force.

80 ) for SCAFI, 0.93 points per year (0.06) for ADL, and -0.02 points per year (0.004) for EQ-5D-3L.

81 OM direction that fulfilled the criteria for ADL (p < 0.001).

82 for any outcome, although risk estimates for ADL disability seemed attenuated in African American rel

83 ged in parallel with HF severity, except for ADL duration in very short (ADL3) and composite (ADL1) a

84 or all covariates, the lowest odds ratio for ADL limitation was for a BMI of 25-<30 (odds ratio = 1.1

85 0.93, 1.30), and the highest odds ratio for ADL limitation was for a BMI of 35 or higher (odds ratio

86 cing standard with HO stems improved ROM for ADL in a low number of patients below 10% (p > 0.03).

87 No group differences were found for ADLs or death.

88 ng the Activities of Daily Living-Long Form (ADL-L) and cognitive status with the Cognitive Performan

89 onths postinjury, a decline of nearly 1 full ADL (P < .05).

90 impaired) and moderately dependent function (ADL-L 14.5 +/- 9.4, range 0-28, where 28 = total depende

91 ated with impaired lower-extremity function, ADLs, and IADLs [odds ratio (95% CI): 0.67 (0.47, 0.95),

92 ated with impaired lower-extremity function, ADLs, and IADLs approximately 9 y later, particularly in

93 nts had died, 9% (CI, 8% to 11%) had further ADL decline, 50% (CI, 48% to 52%) had persistent impairm

94 ed during the 14-year follow-up, and 27% had ADL and 43% had IADL disability at baseline.

95 Higher ADL during early gestation was associated with a lower r

96 akes were inversely associated with impaired ADLs and IADLs [odds ratio (95% CI): 0.60 (0.40, 0.90) a

97 anial direct current stimulation may improve ADLs in adults with stroke.

98 orted use of robotic arm training to improve ADLs.

99 In ADL, unc-1(dn) has effects opposite to those of tetanus

100 luded in this study, 14.6% had disability in ADL and 47.9% in IADL; 59.7% had vitamin D insufficient

101 m-term clinically meaningful improvements in ADL or quality of life in mild to moderate PD.

102 decline correlated with rates of increase in ADL difficulties (r = 0.15, P = 0.05) and IADL difficult

103 fficulties in men and women and increases in ADL difficulties for men only.

104 y disability in instrumental ADLs but not in ADL, or (3) no disability, was assessed from the 2003 he

105 surveyed during 1988-1994, and reductions in ADL impairment observed for nonobese older individuals d

106 sex, increased age, increased dependence in ADLs, and wearing of dentures.

107 le-adjusted odds of having any disability in ADLs versus no disability in people with low risk, any m

108 Impairment in ADLs developed in 22% of participants aged 50 to 64 year

109 ss was significantly related to increases in ADLs for men (b = 0.039, P < 0.01), but not for women (b

110 fair or poor health status or limitations in ADLs or instrumental ADLs, relative to historical trends

111 The high frequency of incident ADL disability attributable to arthritis points to the i

112 omprehensive geriatric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional Assessmen

113 dictive model for 90-day mortality including ADL and Braden Scale yielded C statistics of 0.83 (95% C

114 Mortality increased with increasing ADL difficulty; the hazard ratio (95% confidence interva

115 y disabled older persons recover independent ADL function at rates far exceeding those that have been

116 of H2O2 were much more efficient at inducing ADLs than higher concentrations.

117 ctivities of daily living (ADL)/instrumental ADL (IADL) disability, Centers for Epidemiologic Studies

118 tric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional Assessment (MNA), Mini-Ment

119 ivity of daily living (ADL) and instrumental ADL (IADL) scales.

120 ities of daily living (ADL) and instrumental ADL (IADL).

121 of daily living (ADL) tasks and instrumental ADL.

122 rforming any ADL and 11% in any instrumental ADL only.

123 omen without severe impairment, Instrumental ADL deterioration was significantly less for those livin

124 iving arrangement and change in Instrumental ADL depended on the level of physical impairment.

125 months, as were disabilities in instrumental ADL in 108 (26%) of 422 individuals at 3 months and 87 (

126 alone had a greater decline in Instrumental ADL, especially when compared with those living with non

127 primarily as a deterioration in Instrumental ADL.

128 tal activities of daily living (Instrumental ADL).

129 ties of daily living (ADLs) and instrumental ADLs (IADLs) for which patients needed assistance.

130 ies of daily living (ADLs), and instrumental ADLs (IADLs) self-reported approximately 9 y later in mo

131 ties of daily living (ADLs) and instrumental ADLs (IADLs) were evaluated through survey instruments.

132 The number of ADLs and instrumental ADLs (range, 0-12) that the participant could not perfor

133 f daily living (ADLs) (ADLs and instrumental ADLs), emergency department visits and hospital admissio

134 ties of daily living [ADLs] and instrumental ADLs).

135 Results were similar for instrumental ADLs, in both men and women.

136 of 20 years, and impairment in instrumental ADLs (IADLs), defined similarly.

137 g (ADLs), (2) any disability in instrumental ADLs but not in ADL, or (3) no disability, was assessed

138 tatus or limitations in ADLs or instrumental ADLs, relative to historical trends, were detected.

139 eding personal assistance with 1 or more key ADLs (bathing, dressing, walking, and transferring), was

140 y the intensity of aeolian desertified land (ADL).

141 For each infant, average day length (ADL) was calculated during different cumulative time per

142 we demonstrated that aldehydic DNA lesions (ADLs) were induced in mammalian cells by 10 mM hydrogen

143 at baseline to lower extremity limitations, ADL difficulty, or both 18, 36, and 72 months later.

144 nd impairment in activities of daily living (ADL) (defined as severe or moderate to severe) for adult

145 ility to perform activities of daily living (ADL) (five-point scale) before and after vertebroplasty.

146 f limitations in activities of daily living (ADL) among non-Hispanic white, non-Hispanic black, and H

147 of life measures activities of daily living (ADL) and EQ-5D-3L index.

148 red with several activities of daily living (ADL) and instrumental activities of daily living (IADL)

149 d (IES-R), and the activity of daily living (ADL) and instrumental ADL (IADL) scales.

150 status based on activities of daily living (ADL) and instrumental ADL (IADL).

151 (IADL) and basic Activities of Daily Living (ADL) and trajectories of dependency before death in an e

152 Barthel index of Activities of Daily Living (ADL) and various tests of neurocognitive function, motor

153 th or decline in activities of daily living (ADL) at six months, relative to baseline.

154 characteristics, activities of daily living (ADL) dependency, comorbid conditions, length of hospital

155 ination, Barthel Activities of Daily Living (ADL) Index of general disability, EDSS, a 0-4 ataxia sca

156 Activity of Daily Living (ADL) Index, pulmonary, endocrine and central nervous sys

157 mless chair) and activities of daily living (ADL) limitations (transferring, eating, and dressing).

158 s who reported any activity of daily living (ADL) or instrumental activity of daily living (IADL) imp

159 fe measures: the activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale and EQ

160 o Spanish: the 8 activities of daily living (ADL) question of the Modified Health Assessment Question

161 .5 points on the Activities of Daily Living (ADL) scale between the beginning of chemotherapy and the

162 n (MMSE), the HD Activities of Daily Living (ADL) Scale, and a number of demographic variables (CAG n

163 a modified Katz Activities of Daily Living (ADL) scale, three items from the Rosow-Breslau Functiona

164 ) Scale, and the Activities of Daily Living (ADL) Scale.

165 to perform basic activities of daily living (ADL) tasks and instrumental ADL.

166 Disability in activities of daily living (ADL) was identified from report of inability, avoidance,

167 nd self-reported activities of daily living (ADL) were obtained.

168 ilities in basic activities of daily living (ADL) were present in 139 (32%) of 428 patients at 3 mont

169 h limitations in activities of daily living (ADL) were randomized to physiotherapy and occupational t

170 nce status (PS), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL)

171 ility to perform activities of daily living (ADL), in older patients with asymptomatic primary hyperp

172 Up and Go (GUG), Activities of Daily Living (ADL), Instrumental Activities in Daily Living (IADL), Mi

173 PDRS), scales of activities of daily living (ADL), neuropsychological testing, and PET imaging with 1

174 ed dependence in Activities of Daily Living (ADL), oral symptoms, and presence of a caregiver.

175 nual death rate, Activities of Daily Living (ADL), physical performance in three tests and cognitive

176 h three metrics: activities of daily living (ADL), the Braden Scale, and the Morse fall risk score.

177 on self-reported Activities of Daily Living (ADL).

178 (IADL) and basic activities of daily living (ADL).

179 and a survey of activities of daily living (ADL).

180 es necessary for activities of daily living (ADL).

181 to perform basic activities of daily living (ADL).

182 Frailty, activities of daily living (ADL)/instrumental ADL (IADL) disability, Centers for Epi

183 or difficulty in activities of daily living (ADL; e.g., transferring).

184 , limitations in activities of daily living (ADLs) (ADLs and instrumental ADLs), emergency department

185 ne the number of activities of daily living (ADLs) and instrumental ADLs (IADLs) for which patients n

186 Activities of daily living (ADLs) and instrumental ADLs (IADLs) were evaluated throu

187 ard to mobility, activities of daily living (ADLs) and Modified Rankin Scale (MRS) score at admission

188 in the number of activities of daily living (ADLs) and/or instrumental activities of daily living (IA

189 o limitations in activities of daily living (ADLs) at baseline, 697 remained ADL independent, 84 beca

190 atus survey of 5 activities of daily living (ADLs) at hospital admission and 3, 6, and 12 months post

191 either represent activities of daily living (ADLs) nor fully reproduce patients' symptoms.

192 ifficulty with 9 activities of daily living (ADLs) was assessed by a questionnaire.

193 ny disability in activities of daily living (ADLs), (2) any disability in instrumental ADLs but not i

194 remity function, activities of daily living (ADLs), and instrumental ADLs (IADLs) self-reported appro

195 ility to perform activities of daily living (ADLs), and quality of life (QOL).

196 lity to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on sc

197 Impairment in activities of daily living (ADLs), defined as self-reported difficulty performing 1

198 e assessed using activities of daily living (ADLs), falls, hand-grip, and chair-stands.

199 ed the effect of activities of daily living (ADLs), living conditions, occupational and recreational

200 ility to perform activities of daily living (ADLs), walk one-quarter mile, or lift 10 lbs.

201 d complete basic activities of daily living (ADLs).

202 ation to improve activities of daily living (ADLs).

203 mental and basic activities of daily living (ADLs); and emergency department (ED) visits not resultin

204 and instrumental activities of daily living (ADLs, IADLs), cognition (Mini-Cog test), history of fall

205 vere, persistent activities-of-daily-living (ADLs) disability, defined as dependence in >/=3 ADLs for

206 , functionality (activities of daily living [ADL] + instrumental activities of daily living [IADL]),

207 scale (measuring activities of daily living [ADLs] and instrumental ADLs).

208 In males, ADL sensory responses are diminished; in addition, a sec

209 mum data set-activities of daily living (MDS-ADL), respectively.

210 mum Data Set-Activities of Daily Living [MDS-ADL] scale of 0 to 28 points, with higher scores indicat

211 Mean MDS-ADL self-performance score worsened by 1.2 (0.6 to 1.8)

212 The median MDS-ADL score increased from 12 during the 3 months before t

213 ated by an increase of 2.8 points in the MDS-ADL score (95% confidence interval [CI], 2.5 to 3.0); th

214 uospatial ability (p=0.002), and for the MDS-ADL subitem locomotion on unit (p=0.021).

215 dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL as

216 ssessment, and at least one post-baseline MG-ADL assessment.

217 as the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA.

218 thenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of

219 % of patients had a mean reduction in the MG-ADL of>=2 points in the first cycle and this remained st

220 INTERPRETATION: The change in the MG-ADL score was not statistically significant between ecul

221 controlled with standard-of-care therapy (MG-ADL score >=6) were randomly assigned (1:1) to either ni

222 (59.4%) reported difficulty with one or more ADLs at enrollment, with 272 (24.1%) and 146 (12.9%) exp

223 elf-reported difficulty performing 1 or more ADLs, assessed every 2 years for a maximum follow-up of

224 respectively in the pheromone-sensing neuron ADL and the bacteria-sensing neuron AWA.

225 Expression of unc-1(dn) in RMG hub neurons, ADL or ASK pheromone-sensing neurons, or URX oxygen-sens

226 758 participants ages > or =65 years with no ADL disability at baseline were included in the analyses

227 1.16, 5389.92, 7526.38, and 3752.74 km(2) of ADL in the above 4 periods, accounting for 28.56%, 39.06

228 The associations of ADL difficulty with mortality and hospitalization were a

229 Almost 1 in every 4 new cases of ADL disability was due to arthritis (adjusted population

230 Patients were divided into 3 categories of ADL difficulty (no/minimal, moderate, severe).

231 We studied the effects of ADL 8-2698, an investigational opioid antagonist with li

232 Each additional hour of ADL (90 days) decreased the likelihood of SROP by 28% (P

233 yes developing SROP, each additional hour of ADL during the first 105 days after the EDC decreased th

234 itis had a substantially higher incidence of ADL disability compared with those without arthritis (9.

235 ffect was associated with lower incidence of ADL disability in older Mexican Americans with self-repo

236 Patients given 6 mg of ADL 8-2698 had significantly faster recovery of gastroin

237 ceive one capsule containing 1 mg or 6 mg of ADL 8-2698 or an identical-appearing placebo capsule two

238 Effects in the group that received 1 mg of ADL 8-2698 were less pronounced.

239 an [95% confidence interval [CI]] numbers of ADL dependencies: 0.69 [0.19-1.19] at 12 months before d

240 with high IC had significantly lower odds of ADL difficulty [aOR: 0.63, CI: 0.52-0.76], IADL difficul

241 This was because the odds of ADL impairment did not change for obese individuals but

242 addition, Hispanics reported higher rates of ADL limitations than did non-Hispanic whites with compar

243 t having a larger effect in reducing risk of ADL dependence in men than in women.

244 tive affect (score = 12) and reduced risk of ADL disability 2 years later, controlling for baseline s

245 R 1.37, 0.90-1.91); indeed a reduced risk of ADL impairment appeared after multivariable adjustment (

246 s toxin light chain, separating the roles of ADL electrical and chemical synapses.

247 ls of H2O2 induced a massive accumulation of ADLs.

248 ent in the hospital focused on evaluation of ADLs, mobility, and cognition.

249 cells correlated well with the formation of ADLs.

250 The number of ADLs and instrumental ADLs (range, 0-12) that the partic

251 interval [CI], 0.6-2.6) or in the number of ADLs recovered to premorbid level (difference, 0.09 ADL;

252 ional capacity, and hence the performance of ADLs in asymptomatic, older PHPT patients.

253 and there were no differences in recovery of ADLs for either condition.

254 trongly prognostic for functional decline on ADL and IADL, and G8, fTRST (1), and fTRST (2) were prog

255 holinesterase inhibitors improved 0.1 SDs on ADL scales (95% CI, 0.00-0.19 SDs), and 0.09 SDs on IADL

256 on depending on its expression in the ASJ or ADL sensory neurons, respectively.

257 lso associated with a lower risk of death or ADL dependency 3 months after stroke.

258 a significant difference in ICARS, FARS, or ADL total scores, there were indications of a dose-depen

259 myalgia differed significantly in their pain:ADL ratios, in both languages.

260 1.6; 95% confidence interval 1.05, 2.57, per ADL-L quartile) were independently associated with incre

261 ted pain, ambulation, and ability to perform ADL before and after vertebroplasty were evaluated with

262 Ability to perform ADL was also significantly improved following vertebropl

263 e, and 14.6% died without severe, persistent ADL dependence in the derivation cohort (n = 8,301); the

264 g 5 years, 6.8% developed severe, persistent ADL dependence, and 14.6% died without severe, persisten

265 A decline in IADL usually precedes ADL limitation, including taking medications, and may th

266 Here we show that H2O2 produces ADLs at concentrations as low as 0.06 mM in HeLa cells a

267 sity were associated with new or progressive ADL and IADL disability in a dose-dependent manner, part

268 nt summary of the SF-36, and the HAD, IES-R, ADL and IADL scales.

269 justed OR, 3.3; 95% CI, 1.5-7.2) and recover ADLs (difference, 0.63 ADL; 95% CI, 0.20-1.07).

270 aily living (ADLs) at baseline, 697 remained ADL independent, 84 became ADL dependent, 41 died, and 1

271 on and conflicting evidence on self-reported ADL (changes ranged from -1.38% to 1.53% per year) and v

272 synaptic activity between the ascr#3-sensing ADL neurons and their post-synaptic SMB motor neuron par

273 on remained stable for functional and severe ADL impairment and decreased for moderate-to-severe ADL

274 airment and decreased for moderate-to-severe ADL impairment.

275 to shop for personal items was the specific ADL more commonly retained by the GC group compared with

276 ) in HF and healthy subjects during standard ADLs and other common physical actions.

277 ce interval {CI}, 4.76-13.8] per 10-stands), ADL dependence (-6.06 [-10.8 to -1.36]), opiate use (-5.

278 cores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam.

279 s (self reported) on incidence of subsequent ADL disability after controlling for baseline difference

280 Stratification by age indicated that ADLs were most strongly associated with mortality in the

281 These results suggest that ADLs induced by submillimolar levels of H2O2 may be due

282 The ADL development in north Shanxi was a result of mutual i

283 The ADL sensory neurons detect C9 and, in wild-type hermaphr

284 bilitation hospital is predicted by both the ADL (<12) and Braden Scale (<16), with respective adjust

285 scr#10 requires TRPV channel function in the ADL neurons and the daf-7 signaling from the ASI neurons

286 s were observed for 18.1% of patients on the ADL, 73.0% of patients on the IADL, 24.1% of patients on

287 directs expression of reporter genes to the ADL chemosensory neurons.

288 deterioration of ataxia symptoms over time; ADL is an appropriate measure to monitor changes in dail

289 ity is an independent factor contributing to ADL disability in these populations and should be includ

290 ed in the hyponatremia group with respect to ADL (DeltaADL: 14.3 +/- 17.1 vs. 9.8 +/- 14.7; p = 0.002

291 With respect to ADL impairment, odds for obese individuals were not sign

292 For functional outcomes, 14 trials used ADL and 13 trials used IADL scales.

293 Time windows when ADL was most closely associated with SROP were 31 to 60

294 limitation at baseline, including 12.9% with ADL limitations.

295 CIRS-G grade 3/4 had a fair correlation with ADL (p = 0.27).

296 Correlation of ECOG PS with ADL (p = 0.51)c and IADL (p = 0.61) was moderate.

297 % of survivors reported more difficulty with ADLs and patients with persistently severe or worsening

298 s more likely to have severe difficulty with ADLs, walking, or lifting at baseline compared with wome

299 ted with increased odds of needing help with ADLs (OR, 3.59; 95% CI, 1.94-6.66), while there was no s

300 at baseline, 17% developed new or worsening ADL disability and 26% developed new or worsening IADL d